Home / 2016 / November / 22

Daily Archives: Nov 22, 2016

Nov. 22, 2016

On Monday, the FDA gave approval to NovoNordisk’s new combination product, Xultophy. This is a combination of the super long-acting insulin degludec and the once daily GLP-1 agonist Liraglutide. The fixed dose combination is given in one to 50 dosing steps to maximize to glycemic control. The super long-acting insulin …

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #51: Incretin Physiology in Health and Disease Part 1 of 6

The incretin effect in health: The idea that gastrointestinal factors contribute to the control of postprandial glucose regulation dates back to the beginning of the twentieth century, when Moore and colleagues reported reductions in glucosuria after the oral administration of gut extracts xin patients with juvenile diabetes. Even though it is questionable whether these glucose-lowering effects were really attributable to the incretin activity of the extract (which is unlikely, because most gastrointestinal peptide hormones are inactivated by the gastric acid), this report can be considered as the first description of an incretin-like effect.

Read More »